PDGF-BB/KLF4/VEGF Signaling Axis in Pulmonary Artery Endothelial Cell Angiogenesis

Cell Physiol Biochem. 2017;41(6):2333-2349. doi: 10.1159/000475652. Epub 2017 Apr 27.

Abstract

Background: Accumulating evidence suggests that platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor(VEGF) play a role in the progression of pulmonary arterial hypertension (PAH).Since chronic hypoxia is responsible for intimal hyperplasia and disordered angiogenesis of pulmonary arteries, which are histological hallmarks of PAH, we explored the role of the PDGF-BB/KLF4/VEGF signaling axis in the angiogenesis of pulmonary artery endothelial cells (PAECs).

Methods: Adult male Wistar rats were used to study hypoxia-induced or monocrotaline (MCT)-induced right ventricular (RV) remodeling as well as systolic function and hemodynamics using echocardiography and a pressure-volume admittance catheter. Morphometric analyses of lung vasculature and RV vessels were performed.

Results: The results revealed that both the PDGF receptor-tyrosine kinase inhibitor imatinib and the multi-targeted VEGF and PDGF receptor inhibit or sunitinib malate reversed hypoxia-induced increases in right ventricular systolic pressure (RVSP), right ventricular function and thickening of the medial walls. Mechanistically VEGF/VEGFR and PDGF/PDGFR formed a biological complex. We also showed that PDGF-BBincreasedKLF4 promoter activity transcriptionally activating VEGF expression, which regulates PAEC proliferation; migration; and the cell-cycle transition from G0/G1phase to S phase and G2/M-phase and eventually leads to PAEC angiogenesis Conclusion: Our study indicates that hypoxia-induced angiogenesis of PAECs is associated with increased levels of PDGF-BB/KLF4/VEGF, which contribute to pulmonary vascular remodeling. Overall, our study contributes to a better understanding of PAH pathogenesis.

Keywords: Angiogenesis; Platelet-derived growth factor-BB; Pulmonary artery endothelial cells; Transcription factor Krüppel-like factor 4; Vascular endothelial growth factor.

Publication types

  • Retracted Publication

MeSH terms

  • Animals
  • Becaplermin
  • Cell Hypoxia
  • Cell Movement / drug effects
  • Cell Proliferation
  • Endothelial Cells / cytology
  • Endothelial Cells / metabolism
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • Imatinib Mesylate / pharmacology
  • Indoles / pharmacology
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors / antagonists & inhibitors
  • Kruppel-Like Transcription Factors / genetics
  • Kruppel-Like Transcription Factors / metabolism*
  • Lung / diagnostic imaging
  • Male
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-sis / antagonists & inhibitors
  • Proto-Oncogene Proteins c-sis / genetics
  • Proto-Oncogene Proteins c-sis / metabolism*
  • Pulmonary Artery / cytology
  • Pyrroles / pharmacology
  • RNA Interference
  • Rats
  • Rats, Wistar
  • Signal Transduction* / drug effects
  • Sunitinib
  • Up-Regulation / drug effects
  • Vascular Endothelial Growth Factor A / metabolism*
  • Vascular Remodeling / drug effects

Substances

  • Indoles
  • Klf4 protein, rat
  • Kruppel-Like Factor 4
  • Kruppel-Like Transcription Factors
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-sis
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Becaplermin
  • Imatinib Mesylate
  • Sunitinib